Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes : a Randomized, Double-blind, Placebo-controlled, Cross-over Trial
Latest Information Update: 29 Sep 2022
At a glance
- Drugs Alirocumab (Primary)
- Indications Hypercholesterolaemia; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Acronyms EUTERPE
- 26 Sep 2022 Status changed from recruiting to completed.
- 12 Jan 2021 Planned number of patients changed from 24 to 16.
- 12 Jan 2021 Planned End Date changed from 31 Dec 2021 to 30 Apr 2022.